ライフサイエンスコーパス: PCNSL

1 PCNSL in immunocompetent patients is associated with uni

2 PCNSL incidence was higher in Asians/Pacific Islanders t

3 PCNSL is an uncommon tumor, and only four randomized tri

4 PCNSL is highly dependent on BCR signaling, and ibrutini

5 PCNSL patients without evidence of radiographic disease

6 PCNSL-AS patients exhibited better VA than PVRL patients

7 02 PCNSL), and a testing set (99 GBM and 108 PCNSL).

8 ted of a training set (n = 1894 GBM and 1245 PCNSL), a validation set (n = 339 GBM; 202 PCNSL), and a

9 In 18 PCNSL patients, 94% showed tumor reductions with ibrutin

10 5 PCNSL), a validation set (n = 339 GBM; 202 PCNSL), and a testing set (99 GBM and 108 PCNSL).

11 scape and tumor microenvironment (TME) of 91 PCNSL tissues all with diffuse large B-cell lymphoma his

12 xpression and function were assessed in AIDS-PCNSL biopsy samples and in EBV+ human B-cell tumors tha

13 rimary central nervous system lymphoma (AIDS-PCNSL) is due in part to the intrinsic resistance of thi

14 omponent in the multimodal treatment of AIDS-PCNSL.

15 Cells from two AIDS-PCNSL biopsy samples that did not express pan B-cell mar

16 (OR = 0.14; 95% CI 0.02-1.11; P = 0.06) and PCNSL-S (OR: 0.08; 95% CI 0.01-0.69 P = 0.05) and was as

17 g 320 patients with either GBM (n = 160) and PCNSL (n = 160) from two academic institutions.

18 EBV-associated PCNSL in the immunosuppressed is immunobiologically dist

19 CNSL-S), whereas 10 (37%) were asymptomatic (PCNSL-AS).

20 Because PCNSL may involve the brain, CSF, and eyes, diagnostic e

21 nome-wide gene expression comparison between PCNSL and non-CNS DLBCL was performed, the latter consis

22 ebral endothelial cells upon CNS invasion by PCNSL.

23 Primary lymphoma of the CNS (PCNSL) is a diffuse large B cell lymphoma confined to th

24 lymphoma of the central nervous system (CNS; PCNSL) is the strong CXCR4 expression of the tumor cells

25 In conclusion, PCNSL risk is highly elevated among transplant recipient

26 had undergone repeat brain biopsy to confirm PCNSL.

27 Stereotactic biopsy confirmed PCNSL due to Ebstein-Barr virus reactivation.

28 mpetent adults with histologically confirmed PCNSL after experiencing high-dose methotrexate-based ch

29 utive patients with histologically confirmed PCNSL were collected concurrently with magnetic resonanc

30 in, all 24 brain biopsy specimens containing PCNSL were positive for BCA-1.

31 a true "CNS signature" because we contrasted PCNSL with wide-spectrum non-CNS DLBCL on a genomic scal

32 single-center phase-2 study, newly diagnosed PCNSL patients received 5 to 7 cycles of chemotherapy wi

33 ht consecutive patients with newly diagnosed PCNSL seen at Memorial Sloan-Kettering Cancer Center (MS

34 Forty-four patients with newly diagnosed PCNSL were treated with induction MT-R, and patients who

35 is feasible in patients with newly diagnosed PCNSL without evidence of significant related neurotoxic

36 ll survival in patients with newly diagnosed PCNSL.

37 plicability to patients with newly diagnosed PCNSL.

38 ncreased the probability for differentiating PCNSL and atypical glioblastoma compared with the evalua

39 e diagnostic performance for differentiating PCNSL from glioblastoma was evaluated by using logistic

40 and genetic characteristics that distinguish PCNSL are beginning to be elucidated.

41 ion to assist radiologists in distinguishing PCNSL and GBM.

42 g a preclinical animal model of human EBV(+) PCNSL with subsequent translation to patients with EBV(+

43 Enhanced expression of EBV-TK mRNA in EBV(+) PCNSL tumors by radiation therapy occurred in a dose-dep

44 have developed a preclinical model of EBV(+) PCNSL to explore strategies that specifically target EBV

45 Patients with EBV(+) PCNSL face a particularly poor prognosis with median sur

46 a solid organ transplant patient with EBV(+) PCNSL.

47 bsequent translation to patients with EBV(+) PCNSL.

48 96) and an AUC 0.93 (95% CI = 0.89-0.96) for PCNSL.

49 M and an AUC of 0.94 (95% CI: 0.91-0.97) for PCNSL.

50 wledge that dose-intensive consolidation for PCNSL is feasible in the multicenter setting and yields

51 Future guidelines for PCNSL management should consider the necessity of diagno

52 eral biologic contexts with implications for PCNSL, including CNS tropism (ECM and adhesion-related p

53 splant recipients had elevated incidence for PCNSL compared with the general population (standardized

54 d that this appears to be a prerequisite for PCNSL development, we find no evidence that pleomorphic

55 Combined modality therapy for PCNSL has improved survival, but relapse is common and l

56 h ibrutinib alone, including patients having PCNSL with CD79B and/or MYD88 mutations, and 86% of eval

57 Virus (EBV) positive, in contrast to non-HIV PCNSL and non-CNS AIDS-related lymphomas.

58 nd 44 were EBV tissue-positive: 23 EBV+ HIV+ PCNSL and 21 EBV+ HIV- PCNSL.

59 negative: 45 EBV- HIV- PCNSL and 2 EBV- HIV+ PCNSL; and 44 were EBV tissue-positive: 23 EBV+ HIV+ PCN

60 To counter this, EBV+ HIV- PCNSL had a tolerogenic TME with elevated macrophage and

61 ositive: 23 EBV+ HIV+ PCNSL and 21 EBV+ HIV- PCNSL.

62 seven were EBV tissue-negative: 45 EBV- HIV- PCNSL and 2 EBV- HIV+ PCNSL; and 44 were EBV tissue-posi

63 As with prior studies, EBV- HIV- PCNSL had frequent MYD88, CD79B, and PIM1 mutations, and

64 s immunobiologically distinct from EBV- HIV- PCNSL, and, despite expressing an immunogenic virus, ret

65 tive review was performed of immunocompetent PCNSL patients from 1985 to 2005.

66 s with pathologically proven immunocompetent PCNSL between September 2010 and February 2022.

67 In PCNSL, expression of BCA-1 by malignant lymphocytes and

68 As in PCNSL, the transformation of the tumor cells likely orig

69 ally analyze reported studies on HDC/ASCT in PCNSL and discuss its current role and future perspectiv

70 The rationale for using HDC/ASCT in PCNSL patients is based on the fact that the delivery of

71 alysis of molecular prognostic biomarkers in PCNSL in the setting of a clinical trial.

72 tein level of ECM-related SPP1 and CHI3L1 in PCNSL cells was demonstrated by immunohistochemistry.

73 )(q22) and BCL6 rearrangements are common in PCNSL and predict for decreased OS independent of deep s

74 Subretinal infiltration was less common in PCNSL-AS cases compared to PVRL (OR = 0.14; 95% CI 0.02-

75 lls as a novel mechanism of immune escape in PCNSL.

76 hough intraocular involvement is frequent in PCNSL and clinically marked by slowly progressive visual

77 ed studies detected high EBV copy numbers in PCNSL tumour tissue, and low copy numbers in AIDS cases

78 mic data revealed four molecular patterns in PCNSL with a distinctive prognostic impact that provides

79 ive chemotherapy in this randomized trial in PCNSL, in which neither arm involves WBRT.

80 of high-dose consolidation, without WBRT, in PCNSL.

81 ersus untreated mice with BAL17(CNS)-induced PCNSL.

82 imaging (MRI) according to the International PCNSL Collaborative Group response criteria.

83 IGH), and MYC gene rearrangements in a large PCNSL cohort treated in a single center.

84 , including those with primary CNS lymphoma (PCNSL) (outside the area of neoplastic involvement) cont

85 Primary CNS lymphoma (PCNSL) and primary intraocular lymphoma (IOL) are usuall

86 response assessment of primary CNS lymphoma (PCNSL) are critical to ensure comparability among clinic

87 Primary CNS lymphoma (PCNSL) harbors mutations that reinforce B cell receptor

88 s with newly diagnosed primary CNS lymphoma (PCNSL) in order to establish a predictive model that cou

89 Primary CNS lymphoma (PCNSL) is a rare form of extranodal non-Hodgkin lymphoma

90 Primary CNS lymphoma (PCNSL) is an aggressive lymphoma but clinically validate

91 Primary CNS lymphoma (PCNSL) is an aggressive primary brain tumor.

92 PURPOSE Primary CNS lymphoma (PCNSL) is confined to the CNS and/or the eyes at present

93 ed on 31 patients with primary CNS lymphoma (PCNSL) treated between 1986 and 1992 with methotrexate (

94 atients with recurrent primary CNS lymphoma (PCNSL) were studied.

95 Primary CNS lymphoma (PCNSL), an uncommon form of extranodal non-Hodgkin's lym

96 vival in patients with primary CNS lymphoma (PCNSL).

97 (RT) for patients with primary CNS lymphoma (PCNSL).

98 relapsed or refractory primary CNS lymphoma (PCNSL).

99 es as consolidation in primary CNS lymphoma (PCNSL).

100 -dose methotrexate for primary CNS lymphoma (PCNSL).

101 imary central nervous system (CNS) lymphoma (PCNSL) and primary testicular lymphoma (PTL) are rare ex

102 imary central nervous system (CNS) lymphoma (PCNSL) arising in the intraocular compartment without br

103 imary central nervous system (CNS) lymphoma (PCNSL) is a diffuse large B-cell lymphoma (DLBCL) confin

104 imary central nervous system (CNS) lymphoma (PCNSL) were excluded from all pivotal CAR-T studies.

105 sease, and primary central nervous lymphoma (PCNSL).

106 ith primary central nervous system lymphoma (PCNSL) are treated with high-dose methotrexate-based che

107 of primary central nervous system lymphoma (PCNSL) at postcontrast T1-weighted MRI.

108 Primary central nervous system lymphoma (PCNSL) in HIV patients has declined in incidence and the

109 Primary central nervous system lymphoma (PCNSL) is a diffuse large B cell lymphoma in which the b

110 Primary central nervous system lymphoma (PCNSL) is a rare and distinct entity within diffuse larg

111 Primary central nervous system lymphoma (PCNSL) is a rare but often rapidly fatal form of non-Hod

112 Primary central nervous system lymphoma (PCNSL) is a rare extranodal lymphomatous malignancy that

113 Primary central nervous system lymphoma (PCNSL) is an aggressive B cell lymphoma that occurs in i

114 in primary central nervous system lymphoma (PCNSL) is caused mostly by intraocular lymphomatous invo

115 Primary central nervous system lymphoma (PCNSL) is confined to the brain, eyes, and cerebrospinal

116 of primary central nervous system lymphoma (PCNSL) patients with a small volume of CSF, presenting a

117 Primary central nervous system lymphoma (PCNSL) represents 1% to 3% intracranial tumors.

118 Primary central nervous system lymphoma (PCNSL) risk is greatly increased in immunosuppressed hum

119 Primary central nervous system lymphoma (PCNSL) that arises in immune-deficient patients is an ag

120 Primary central nervous system lymphoma (PCNSL) treatment includes 2 phases: induction and consol

121 sed primary central nervous system lymphoma (PCNSL) using induction immunochemotherapy (rituximab, hi

122 of primary central nervous system lymphoma (PCNSL), but relapses remain frequent.

123 of primary central nervous system lymphoma (PCNSL).

124 of primary central nervous system lymphoma (PCNSL).

125 of primary central nervous system lymphomas (PCNSL) are difficult to distinguish from glioblastoma mu

126 orphic infiltrates represent a pre-malignant PCNSL state.

127 Most PCNSL are located in the brain, and 75% are large B-cell

128 o explain, at least in part, the affinity of PCNSL cells for the CNS.

129 rs, we have analyzed V(H) gene of 5 cases of PCNSL, all confirmed by histological studies to be Epste

130 be included into the therapeutic concept of PCNSL.

131 The diagnosis of PCNSL requires a high level of suspicion because clinica

132 ain lesions strongly suggests a diagnosis of PCNSL.

133 of PWI and DWI facilitated the diagnosis of PCNSL.

134 of ITSS allowed reliable differentiation of PCNSL and atypical glioblastoma in most patients, and th

135 To identify targetable genetic features of PCNSL and PTL, we characterized their recurrent somatic

136 The incidence of PCNSL is rising in immunocompetent patients over the age

137 f therapy and address the quality of life of PCNSL survivors.

138 The majority of PCNSL patients who received corticosteroids before diagn

139 re improving the diagnosis and management of PCNSL.

140 Novel insights into the pathophysiology of PCNSL have identified key mechanisms in tumor pathogenes

141 a discussion of the clinical presentation of PCNSL, the approach to work-up and staging, and an overv

142 an atypical and challenging presentation of PCNSL.

143 In general, the prognosis of PCNSL has improved significantly over the past few decad

144 ccurate and robust automatic segmentation of PCNSL across multiple clinical centers with different MR

145 ing early detection of VRL in the staging of PCNSL.

146 ns remain regarding the optimal treatment of PCNSL, in general, and unusual variants of PCNSL.

147 advances have improved our understanding of PCNSL, the need for additional collaborative research is

148 f PCNSL, in general, and unusual variants of PCNSL.

149 mes that are comparable or superior to other PCNSL treatment regimens.

150 , or asymptomatic VRL associated with PCNSL (PCNSL-AS).

151 VRL), symptomatic VRL associated with PCNSL (PCNSL-S), or asymptomatic VRL associated with PCNSL (PCN

152 Rarely, PCNSL occurs in the context of immunosuppression (eg, po

153 In vivo trials using the nude rat PCNSL model demonstrated significantly improved mean sur

154 Compared to kidney recipients, PCNSL incidence was lower in liver recipients (adjusted

155 ns for patients with relapsed and refractory PCNSL and PTL, and the overall prognosis is poor.

156 R-CHOP in patients with relapsed/refractory PCNSL (NCT03536039).

157 umab, in 4 patients with relapsed/refractory PCNSL and 1 patient with CNS relapse of PTL.

158 nical response rates for relapsed/refractory PCNSL and are increasingly used for the treatment of rec

159 t nivolumab is active in relapsed/refractory PCNSL and PTL and support further investigation of PD-1

160 Virtually all AIDS-related PCNSL are known to be Epstein-Barr Virus (EBV) positive,

161 s showed EBV positivity only in AIDS-related PCNSL cases within the lymphoma deposits.

162 kpoint gene expression, whereas AIDS-related PCNSL had low CD4 gene counts.

163 However, the incidence of AIDS-related PCNSL, which is related to Epstein-Barr virus infections

164 proliferative disorders or HIV [AIDS-related PCNSL]).

165 tive Radiation Therapy Oncology Group (RTOG) PCNSL clinical trials was used to test the RPA classific

166 17 cancer registries (1987-2014), we studied PCNSL and systemic non-Hodgkin lymphoma (NHL) in 288 029

167 MRI techniques such as DWI and PWI suggested PCNSL.

168 ng these, 17 (63%) reported visual symptoms (PCNSL-S), whereas 10 (37%) were asymptomatic (PCNSL-AS).

169 is with the program SigPathway revealed that PCNSL is characterized notably by significant differenti

170 We developed an algorithm to identify the PCNSL subtypes using RNA-seq data from either FFPE or FF

171 Thus, PCNSL Ig may recognize CNS proteins as self-Ags.

172 rminal center formation in the brain tissue, PCNSL is derived from a B cell with features associated

173 tion is an effective therapeutic approach to PCNSL, but neurotoxicity is a delayed risk of this appro

174 e III EBV gene expression profile similar to PCNSL that develops in some immune-deficient patients.

175 ients (18 to 60 years of age) with untreated PCNSL were randomly assigned to receive WBRT or ASCT as

176 ncluding all Abs derived from IGHV4-34 using PCNSL, recognized galectin-3, which was upregulated on m

177 CNSL-S), or asymptomatic VRL associated with PCNSL (PCNSL-AS).

178 VRL (PVRL), symptomatic VRL associated with PCNSL (PCNSL-S), or asymptomatic VRL associated with PCN

179 features of asymptomatic VRL associated with PCNSL, characterized by better VA and less severe ocular

180 48%) were diagnosed with VRL associated with PCNSL.

181 A total of 752 patients diagnosed with PCNSL were retrospectively identified from the databases

182 mmunocompetent patients newly diagnosed with PCNSL.

183 TSS was significantly lower in patients with PCNSL (32% [six of 19]) than in those with glioblastoma

184 c results in 95% (18 of 19) of patients with PCNSL and 96% (27 of 28) of patients with atypical gliob

185 cleucel in a highly refractory patients with PCNSL and significant unmet medical need.

186 The prognosis of patients with PCNSL has improved during the last decades with the intr

187 The outcome for patients with PCNSL is rapidly improving with new treatment strategies

188 Vs were significantly lower in patients with PCNSL than in those with glioblastoma (P < .01, respecti

189 brain biopsy specimens from 24 patients with PCNSL to investigate the expression of B cell-attracting

190 diagnosed (with no prior WBRT) patients with PCNSL treated with osmotic BBBD and intra-arterial (IA)

191 Forty-five patients with PCNSL were accrued.

192 eficiency virus (HIV)-negative patients with PCNSL were entered on study and received two (n = 20) or

193 e consolidation treatments for patients with PCNSL who are 60 years of age and younger.

194 For patients with PCNSL who experience treatment failure with methotrexate

195 present results of 12 relapsed patients with PCNSL who were treated with tisagenlecleucel and followe

196 In patients with PCNSL, serum levels of YKL-40 and MMP-9 are associated w

197 irradiation in newly diagnosed patients with PCNSL.

198 ove survival over RT alone for patients with PCNSL.

199 lastoma and 19 immunocompetent patients with PCNSL.

200 d treatment of immunocompetent patients with PCNSL.

201 ot MMP-9, predicts survival in patients with PCNSL.

202 wly diagnosed, immunocompetent patients with PCNSL; 98 were assessable.

203 active in relapsed/refractory patients with PCNSL; however, responses were usually short lived.

204 Recipients with PCNSL also had higher mortality than those with systemic

205 Compared to other recipients, those with PCNSL had increased risk of death (adjusted hazard ratio